Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia (ITP) is chronic autoimmune condition that affects the blood. It happens when the body’s immune system mistakenly attacks its own platelets, the cells that help the blood to clot. This leads to the destruction of platlets, resulting in a lower-than-normal number of platelets, which puts patients at risk for bruising, bleeding episodes, hemorrhage and fatigue.

Unmet need

There is a high unmet need in ITP, and limited treatment options. The majority of patients are not controlled by steroids, and many progress on standard second line therapy. Rituximab is also used, however only ~20% of patients maintain remission over time.

85k patients in
the US alone

~80% patients fail first line steroids;
40% progress 
after TPO-RAs

80% of patients
relapse on Rituximab

How budoprutug may be able to help

B cell depleting therapies such as budoprutug are a promising potential treatment approach for ITP because they work to eliminate the problematic B cells that produce the autoantibodies that cause the disease.

Budoprutug targets CD19, which has broad expression across many types of B cells, including autoantibody producing cells.

Support and Resources

Living with Immune Thrombocytopenia (ITP) can be challenging, but you are not alone. There are organizations, support groups, and trusted resources that can help you better understand your condition, connect with others, and find the support you need.